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Abstract
In the present studies, we investigated the correlation
between RASSF1A promoter methylation status and
Kras2 mutations in 65 primary non small cell lung
cancer (NSCLC) including 33 adenocarcinomas, 12
large cell carcinomas, and 20 squamous cell carcino-
mas. Mutational analysis of Kras2 showed: 30% (10 of
33) of adenocarcinomas, 25% (3 of 12) of large cell
carcinomas, and only 5% (1 of 20) of squamous cell
carcinomas contained activated Kras2 mutation at
codon 12 or 13. RASSF1A promoter region CpG island
methylation was detected in adenocarcinomas (55%),
large cell carcinomas (25%), and squamous cell
carcinomas (25%). Interestingly, combined RASSF1A
methylation and Kras2 mutation data show that only
f7% adenocarcinomas/large cell carcinomas ex-
hibited both KRASSF1A promoter methylation and
Kras2 mutation, whereas 24% adenocarcinomas, 50%
large cell carcinomas, and 70% squamous cell carci-
nomas showed neither Kras2 mutation nor RASSF1A
promoter methylation. These results showed that the
majority of the primary NSCLCs with Kras2 mutations
lack RASSF1A inactivation, and both RASSF1A inacti-
vation and Kras2 mutation events occur frequently in
adenocarcinomas and large cell carcinomas. Our
results indicate a trend of inverse relationship between
Kras2 activation and RASSF1A promoter methylation
in the majority of human lung adenocarcinomas and
large cell carcinomas.
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Introduction
Lung cancer is the leading cause of cancer death in men
and women in the US [1]. Molecular changes in proto-
oncogenes and tumor suppressor genes have been
detected in all stages of lung tumorigenesis. Activating
point mutations in the ras genes have been implicated in
the pathogenesis of several human cancers including
those of the lung, colon, and pancreas [2]. In particular,
non small cell lung cancer (NSCLC), which accounts for 75%
of lung cancers, has been shown to harbor Kras2 mutations
in 30% to 50% of lung adenocarcinomas. However, Kras2
mutations were rarely detected in lung squamous cell carci-
nomas [3–7].
RASSF1A, a newly discovered Ras effector, is inactivated in
a variety of human cancers including lung, colon, breast,
prostate, thyroid, and renal cell carcinomas [8–15]. Allelic loss
at 3p21.3 is one of the common events in the pathogenesis of
lung cancer and many other cancers [14]. RASSF1 gene at
3p21.3 encodes two major transcripts, RASSF1A and
RASSF1C. Both RASSF1A and RASSF1C proteins possess the
RAS-binding domain, which binds RAS in a GTP-dependent
manner in vivo and in vitro [15]. The binding of RASSF1 to
Mst1, in conjunction with the binding of Nore1 (a closely related
family member of RASSF1) to Mst1, appears to activate a
proapoptotic pathway [15–17]. It has been proposed that Ras
can activate this proapoptotic pathway by utilizing the Ras
association domain of RASSF1 and Nore1. Of interest to
tumorigenesis is the observation that expression of the splice
variant RASSF1A is absent in lung cancer lines and in primary
tumors [13,14,18,19]. One allele of RASSF1A is lost (the
3p21.3 locus) in a high percentage of all lung cancer subtypes
and expression of the other allele is inhibited by promoter
methylation [18–21]. The RASSF1A promoter is hypermethy-
lated in 72% to 79% of small cell lung cancers and in 30% to
40% of NSCLCs [19,21]. Also, expression of RASSF1A in lung
carcinoma cells was shown to reduce colony formation, sup-
press anchorage-independent growth, and inhibit tumor for-
mation in nude mice [18]. These data suggest that RASSF1A is
a tumor suppressor gene and is inactivated in a high percent-
age of human lung tumors. Other studies have found that
RASS1A is a tumor suppressor in numerous other types of
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cancers, including breast, ovary [11–14], colon [22], head
and neck [23], and prostate [24] cancers.
A recent observation indicates the possibility that acti-
vation of the Ras gene and hypermethylation of the
RASSF1A gene are disjointed events. Van Engeland et
al. [22] detected oncogenic Kras2 mutations in 87 of 222
colorectal tumors and RASSF1A promoter methylation in
45 of these tumors. Only 11 of these tumors (5%) exhibited
both genetic alterations and 110 (50%) contained either
Kras2 mutations or promoter methylation [22]. Similarly, a
study of 110 NSCLCs exhibited Kras2 mutations in 13
tumors and RASSF1A promoter methylation in 35 tumors,
and only two tumors had the same mutation whereas 46
had either a Kras2 oncogene or RASSF1A promoter meth-
ylation [19]. These data suggest that inactivation of
RASSF1A occurs predominantly in colorectal tumors
and adenocarcinomas of the lung without alteration of the
Kras2 gene.
The purpose of this study was to examine the association
between Kras2 mutation and RASSF1A methylation in
human lung adenocarcinomas, large cell carcinomas, and
squamous cell carcinomas, and to determine if there was an
inverse correlation between genetic alterations of RASSF1A
and Kras2.
Materials and Methods
Tissues and DNA Isolation
A total of 65 pathologically documented lung NSCLCs
were used in the present study. These tumors and their
paired normal tissues were obtained from the Cooperative
Human Tissue Network of the Ohio State University Depart-
ment of Pathology (Columbus, OH). A pathologist classified
all tumors histopathologically. High-molecular-weight DNA
was isolated from both tumor and normal tissues according
to published protocols [25].
Analysis of Kras2 Mutations by Polymerase Chain Reaction
(PCR) Direct Sequencing
PCRamplifications ofKras2 exon 1 from lung tumorswere
carried out as described previously [26]. The sequences of
PCR primers of Kras2 exon 1 were Kras2-1F: 5V-TTTTT-
ATTATAAGGCCTGCT-3V and Kras2-1R: 5V-GTCCA-
CAAAATGATTCTGAA-3V. The 114-bp PCR products were
eluted by using QIAquick gel extraction kit (Qiagen, Valen-
cia, CA). The 12th and 13th codon mutations were analyzed
on the ABI PRISM 3700 DNA analyzer (Perkin-Elmer/
Applied Biosystems, Foster City, CA).
Methylation Analyses
The methylation status of the RASSF1A promoter region
was determined by chemical modification of genomic DNA
with sodium bisulfite and methylation-specific PCR (MSP)
wasperformed.Bisulfite treatment converts cytosine bases to
uracil bases but has no effect on methylcytosine bases. The
144-bp fragment of the RASSF1A promoter region was
amplified using: F: 5V-GTT TAG TTT GGA TTT TGG GGG
AG-3V; and R: 5V-CCC RCA ACT CAA TAA ACT CAA ACT C-
3V. The reactionwas incubatedat 95jCfor 1minute, 56jCfor 1
minute, 72jC for 1 minute, and 35 cycles. The PCR product
was used as a template for the MSP reaction. Primers for the
unmethylated reaction were: F: 5V-GGG GTT TGT TTT GTG
GTT TTG TTT-3V; and R: AAC ATAACCCAA TTA AACCCA
TAC TTC A-3V. Primers for the methylated reaction were: F:
5V-GGG TTC GTT TTG TGG TTT CGT TC-3V; and R: 5V-TAA
CCC GAT TAA ACC CGT ACT TCG-3V. The annealing
temperature was 60jC. DNA from normal lung tissue was
used as the control for unmethylated RASSF1A, and normal
lung DNA treated with Sss1 methyltransferases was used as
the control for methylated RASSF1A. H2O was used as
negative control. Twenty microliters of each PCR reaction
was loaded onto a 6% nondenaturing polyacrylamide gel,
stained with ethidium bromide, and pictured under UV light.
Results
Methylation Status of the RASSF1A
A total of 65 primary NSCLCs including 33 adenocarci-
nomas, 12 large cell carcinomas, and 20 squamous cell
carcinomas were analyzed for RASSF1A promoter methyl-
ation. As shown in Table 1, 18 of 33 (55%) adenocarcino-
mas, 3 of 12 (25%) large cell carcinomas, and 5 of 20 (25%)
squamous cell carcinomas were detected with RASSF1A
promoter methylation. Figure 1A illustrates the representa-
tive MSP analysis on pairs of tumors and normal tissues.
Kras2 Gene Mutation
Using PCR direct sequencing analysis, Kras2 gene 12th
and 13th codon mutations were determined in all the NSCLC
DNA. In agreement with previous reports, our data showed
that 10 of 33 (30%) adenocarcinomas, 3 of 12 (25%) large
cell carcinomas, and only 1 of 20 (5%) squamous cell
carcinomas contained the Kras2 gene mutation at codon
Table 1. Correlation Between the Kras2 Activation and RASSF1A Methylation in NSCLCs.
Tumor Type Patient
Number
Kras2 Mutation RASSF1A
Methylation
Tumors Contain
Kras2 Mutations and
RASSF1A Methylation
Tumors Contain Neither
Kras2 Mutations nor
RASSF1A Methylation2Codon 12 Codon 13 Total
Adenocarcinoma 33 8/33 (24%) 2/33 (6%) 10/33 (30%) 18/33 (55%) 3/33 (9%) 8/33 (24%)
Large cell carcinoma 12 3/12 (25%) 0/12 (0%) 3/12 (25%) 3/12 (25%) 0/12 (0%) 6/12 (50%)
Squamous cell carcinoma 20 1/20 (5%) 0/20 (0%) 1/20 (5%) 5/20 (25%) 0/5 (0%) 14/20 (70%)
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12 (GGT!TGT, CGT, GAT, GCT, and GTT transition) or
codon 13 (GGC!GAC, TGC) (Figure 1B, Table 1).
Correlations Between Kras2 Mutation and RASSF1A
Inactivation
By combing RASSF1A promoter methylation analysis
with Kras2 mutation data, we found that only 3 of 33 (9%)
of the samples contained both a Kras2 mutation and
RASSF1A promoter methylation. None of the large cell
carcinomas (zero of three) or squamous cell carcinomas
(zero of five) with RASSF1A promoter methylation contained
a Kras2 mutation (Table 1). Our results indicate that the
majority of the adenocarcinomas and large cell carcinomas
with Kras2 mutations lack RASSF1A promoter methylation.
In addition, 8 of 33 (24%) adenocarcinomas, 6 of 12 (50%)
large cell carcinomas, and 14 of 20 (70%) squamous cell
carcinomas contain neither Kras2 mutation nor RASSF1A
methylation (Table 1). By integrating previous studies
[19,22], a comparison of RASSF1A methylation and Kras2
mutation data was complied and summarized in Table 2.
These data show that onlyf7% adenocarcinomas/large cell
carcinomas, 2% stage I lung adenocarcinomas, and 5%
colorectal tumors exhibited both RASSF1A promoter methyl-
ation and Kras2 mutations.
Discussion
In the present study, we systematically evaluated the corre-
lation between activating Kras2 mutations and RASSF1A
promoter methylation in 33 human lung adenocarcinomas,
12 large cell carcinomas, and 20 squamous cell carcinomas.
We have shown that 30% of the adenocarcinomas, 25% of
large cell carcinomas, and only 5% of the squamous cell
carcinomas contained activating Kras2 mutation at codon
12 or 13. In addition, we analyzed the methylation status of
the promoter region of the RASSF1A gene. Our results
showed that RASSF1A inactivation was observed in 55%
of adenocarcinomas, 25% large cell carcinomas, and 25%
squamous cell carcinomas. When Kras2 mutations and
RASSF1A methylation analysis data were combined, we
found that only 9% of lung adenocarcinomas and none of
Figure 1. Kras2 mutation analysis and MSP analysis of RASSF1A in NSCLCs. (A) Representative autoradiograph showing RASSF1A promoter hypermethylation
in tumors. Tumor identification numbers were indicated above each autoradiograph; the presence of a visible PCR product in those lanes marked M indicated
tumor presence of methylated RASSF1A alleles, whereas the presence of a visible PCR product in those lanes marked U indicated tumor presence of
unmethylated RASSF1A alleles. Normal lung tissue (NL) and in vitro methylated DNA (MC) were used as negative and positive controls for RASSF1A promoter
methylation. H2O was also included in each reaction as negative control. (B) Representative example of 12th and 13th codon mutations in Kras2. Lung tumor
without Kras2 mutation is shown on the left. Lung tumor with Kras2 12th codon mutation (GGT!GAT transition) is shown in the middle. Lung tumor with Kras2 13th
codon mutation (GGC!TGC transition) is shown on the right.
Table 2. Kras2 Mutation and RASSF1A Methylation in Human Lung and
Colon Cancers.
Genetic Changes Lung
Adenocarcinomas
and Large Cell
Carcinomas*
Stage I
Lung
Adenocarcinomasy
Colon
Cancerz
Kras2 mutation and
RASSF1A methylation
3 (7%) 2 (2%) 11 (5%)
Kras2 mutation only 10 (22%) 11 (10%) 76 (34%)
RASSF1A
methylation only
18 (40%) 33 (30%) 34 (15%)
Neither Kras2
mutation or
RASSF1A methylation
14 (31%) 64 (58%) 101 (46%)
Total tumors examined 45 110 222
*The present study.
yTomizawa et al. [19].
zVan Engeland et al. [22].
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large and squamous cell carcinomas contains both a Kras2
mutation and RASSF1A methylation. These data, together
with previous study [19], indicated that the majority of lung
adenocarcinomas and large cell carcinomas with Kras2
mutations lack RASSF1A promoter methylation. Our results
also showed that 24% adenocarcinomas, 50% large cell
carcinomas, and 70% squamous cell carcinomas contain
neither a Kras2 mutation nor RASSF1A methylation. These
data provide evidence that some other alternative pathways
might be involved in human lung tumorigenesis other than
Kras2 mutation and RASSF1A hypermethylation.
As shown in Table 2, our results are highly consistent with
two recently published studies. Van Engeland et al. [22]
evaluated Kras2 mutations and RASSF1A promoter methyl-
ation in colorectal cancer. They found that the majority of
colorectal cancers with Kras2 mutation lack RASSF1A pro-
moter methylation. Another report by Tomizawa et al. [19]
found that only 2% of lung adenocarcinomas with RASSF1A
hypermethylation showed Kras2-activating mutation [19].
They showed that RASSF1A methylation occurs more
frequently in poorly differentiated tumors than in well-
differentiated tumors, suggesting that RASSF1A plays an
important role in the progression of lung adenocarcinoma
and that RASSF1A hypermethylation is a marker for prog-
nosis of patients with stage I lung adenocarcinoma [19].
The Ras effector, RASSF1A, suppressed the tumorige-
nicity of lung cancer cells in a manner similar to wild-type
Ras, suggesting that RASSF1A could be an effector of wild-
type Ras genes, which were recently found to be potent
tumor suppressors [27,28]. Thus, loss of RASSF1A expres-
sion by methylation in human cancer would not require the
event of Ras activation. Interestingly, Kras2 mutations are
found in less than 1% of SCLCs, whereas inactivation of
RASSF1A is close to 80% or 100% by hypermethylation and
loss of heterozygosity (LOH) [9]. Therefore, these results
raise the possibility that the wild-type Ras–RASSF1 signal-
ing pathway suppresses lung cancer cell proliferation and
malignant transformation, and loss of this controlling function
by either Kras2 point mutation/LOH or RASSF1A promoter
methylation/LOH may result in tumorigenesis. Because
RASSF1A has the identical RAS associate domain as
RASSF1C, RASSF1C likely binds RAS in a GTP-dependent
manner. Therefore, it is possible that RASSF1A shares the
same binding manner as RASSF1C [15]. Feig and Buchs-
baum [16] and Khokhlatchev et al. [17] suggested that Ras
could both promote apoptosis through its association with a
Nore1–RASSF1–Mst1 complex and suppress apoptosis
through its activation of PI3 kinase.
Inverse correlation between tumor suppressor genes
involved in the same signaling pathways has been previously
noted (e.g., inactivation of both p16 and Rb is rarely observed
in the same tumor). The identification ofRASSF1A as a tumor
suppressor gene and a downstream effector of Ras in a
proapoptotic pathway suggests that Ras can promote both
apoptosis and cell survival (by the previously described PI3-K
pathway). With this information on the correlation between
genetic alterations of RASSF1A and Kras2 during tumor-
igenesis, future studies should examine the ability of
RASSF1A to function as a tumor suppressor gene in exper-
imental lung tumorigenesis and the mechanism through
which this novel tumor suppressor gene mediates its effect.
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